PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years

Exclusion Criteria

• •LPA diagnosis according to WHO criteria
• •Previously untreated AML, except for the administration of hydroxyurea as a cytoreductive agent which itself is permitted
• •AML secondary to chronic myeloproliferative syndrome
• •Age\> 65 years
• •ECOG performance status\> 2
• •Absence of written informed consent
• •Being unable to comply with protocol procedures
• •Be fertile and not willing to use a method of birth control during treatment and until the end of it
• •Hypersensitivity to any drug protocol
• •Positive for HIV
• •Abnormal liver and renal functions as indicated below, provided the changes, which would be not due to the disease: Total bilirubin\> 1.5 x upper limit of normal (ULN) institutional and AST and ALT\> 2.5 x ULN, and serum creatinine\> 2.5 mg / dL
• •Altered cardiac function determined by at least 1 of the following:
• •Left ventricular ejection fraction (LVEF) \<40% measured by echocardiography in multiport scanner acquisition (MUGA) or isotope angiography, or Left ventricular fractional shortening \<22% measured by echocardiography